Elan announces launch of extended release Ampyra in U.S.

Following its approval earlier this year, Elan Drug Technologies has announced the launch of Ampyra (dalfampridine) by Acorda Therapeutics in the U.S. as a treatment to improve walking in patients with multiple sclerosis. The first NDA approved and launched incorporating Elan's MXDAS technology, Ampryra was developed using a hydrophilic matrix, which controls the rate of release of dalfampridine through a process of diffusion and erosion in the gastrointestinal tract. Release